Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.719
Sell
RSI(14)
45.593
Neutral
STOCH(KDJ)(9,3,3)
33.472
Buy
ATR(14)
1.830
Low Volatility
CCI(14)
-58.534
Neutral
Williams %R
70.322
Sell
TRIX(12,20)
-0.368
Sell
StochRSI(14)
100.000
Buy
NewAmsterdam Pharma Company NV
NAMS35.110USD
+1.210+3.57%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
3.97BMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of NewAmsterdam Pharma Company NV
Currency: USD Updated: 2025-12-19Key Insights
NewAmsterdam Pharma Company NV's fundamentals are relatively very healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 55/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 47.15.In the medium term, the stock price is expected to trend up.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
NewAmsterdam Pharma Company NV's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
15
analysts
Buy
Current Rating
47.154
Target Price
+31.90%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
NewAmsterdam Pharma Company NV Highlights
StrengthsRisks
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.
Growing
The company is in a growing phase, with the latest annual income totaling USD 45.56M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 45.56M.
Undervalued
The company’s latest PE is -17.20, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 121.74M shares, increasing 3.27% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 479.00 shares of this stock.
Financial Health
Currency: USD Updated: 2025-12-19The current financial score of NewAmsterdam Pharma Company NV is 6.32, ranking 277/404 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 348.00K, representing a year-over-year decrease of 98.80%, while its net profit experienced a year-over-year decrease of 332.54%.
Score
Financials
9.95
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
6.95
Operational Efficiency
2.83
Growth Potential
4.81
Shareholder Returns
7.07
NewAmsterdam Pharma Company NV's Company Valuation
Currency: USD Updated: 2025-12-19The current valuation score of NewAmsterdam Pharma Company NV is 6.93, ranking 206/404 in the Biotechnology & Medical Research industry. Its current P/E ratio is -17.20, which is -88.02% below the recent high of -2.06 and -47.35% above the recent low of -25.35.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 55/404
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-19The current earnings forecast score of NewAmsterdam Pharma Company NV is 8.80, ranking 48/404 in the Biotechnology & Medical Research industry. The average price target for NewAmsterdam Pharma Company NV is 45.00, with a high of 60.00 and a low of 37.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
15
analysts
Buy
Current Rating
47.154
Target Price
+31.90%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
534
Total
6
Median
6
Average
Company name
Ratings
Analysts
NewAmsterdam Pharma Company NV
NAMS
15
CRISPR Therapeutics AG
CRSP
30
argenx SE
ARGX
25
Intellia Therapeutics Inc
NTLA
25
IQVIA Holdings Inc
IQV
25
Ionis Pharmaceuticals Inc
IONS
24
1
2
3
...
107
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-19The current price momentum score of NewAmsterdam Pharma Company NV is 7.02, ranking 164/404 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 40.46 and the support level at 31.31, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
34.452
Buy
MA10
35.184
Sell
MA20
36.859
Sell
MA50
37.192
Sell
MA100
31.599
Buy
MA200
25.697
Buy
Institutional Confidence
Currency: USD Updated: 2025-12-19The current institutional shareholding score of NewAmsterdam Pharma Company NV is 10.00, ranking 1/404 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 107.54%, representing a quarter-over-quarter decrease of 6.38%. The largest institutional shareholder is Andreas Halvorsen, holding a total of 6.48M shares, representing 5.71% of shares outstanding, with 8.12% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Frazier Life Sciences Management, L.P.
RA Capital Management, LP
Capital World Investors
Forbion Capital Partners
Bain Capital Life Sciences Investors, LLC
Fidelity Management & Research Company LLC
Deerfield Management Company, L.P.
Jennison Associates LLC
Wellington Management Company, LLP
1
2
Risk Assessment
Currency: USD Updated: 2025-12-19The current risk assessment score of NewAmsterdam Pharma Company NV is 5.53, ranking 49/404 in the Biotechnology & Medical Research industry. The company's beta value is 0.11. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.11
VaR
--
240-Day Maximum Drawdown
+42.78%
240-Day Volatility
+68.55%
Return
Best Daily Return
60 days
+12.26%
120 days
+12.26%
5 years
--
Worst Daily Return
60 days
-9.84%
120 days
-9.84%
5 years
--
Sharpe Ratio
60 days
+2.12
120 days
+2.61
5 years
--
Risk Assessment
Maximum Drawdown
240 days
+42.78%
3 years
+64.80%
5 years
+100.00%
Return-to-Drawdown Ratio
240 days
+0.84
3 years
+0.94
5 years
+0.49
Skewness
240 days
+0.13
3 years
+2.54
5 years
--
Volatility
Realised Volatility
240 days
+68.55%
5 years
--
Standardised True Range
240 days
+4.31%
5 years
+4.44%
Downside Risk-Adjusted Return
120 days
+457.62%
240 days
+457.62%
Maximum Daily Upside Volatility
60 days
+51.06%
Maximum Daily Downside Volatility
60 days
+37.22%
Liquidity
Average Turnover Rate
60 days
+0.79%
120 days
+0.80%
5 years
--
Turnover Deviation
20 days
+41.05%
60 days
+54.67%
120 days
+57.79%
Peer Comparison
Biotechnology & Medical Research
NewAmsterdam Pharma Company NV
NAMS
7.34 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Amicus Therapeutics Inc
FOLD
8.80 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.42 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Charles River Laboratories International Inc
CRL
8.41 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Madrigal Pharmaceuticals Inc
MDGL
8.35 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.30 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of NewAmsterdam Pharma Company NV?
The TradingKey Stock Score provides a comprehensive assessment of NewAmsterdam Pharma Company NV based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of NewAmsterdam Pharma Company NV’s performance and outlook.
How do we generate the financial health score of NewAmsterdam Pharma Company NV?
To generate the financial health score of NewAmsterdam Pharma Company NV, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects NewAmsterdam Pharma Company NV's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of NewAmsterdam Pharma Company NV.
How do we generate the company valuation score of NewAmsterdam Pharma Company NV?
To generate the company valuation score of NewAmsterdam Pharma Company NV, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare NewAmsterdam Pharma Company NV’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of NewAmsterdam Pharma Company NV’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of NewAmsterdam Pharma Company NV.
How do we generate the earnings forecast score of NewAmsterdam Pharma Company NV?
To calculate the earnings forecast score of NewAmsterdam Pharma Company NV, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on NewAmsterdam Pharma Company NV’s future.
How do we generate the price momentum score of NewAmsterdam Pharma Company NV?
When generating the price momentum score for NewAmsterdam Pharma Company NV, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of NewAmsterdam Pharma Company NV’s prices. A higher score indicates a more stable short-term price trend for NewAmsterdam Pharma Company NV.
How do we generate the institutional confidence score of NewAmsterdam Pharma Company NV?
To generate the institutional confidence score of NewAmsterdam Pharma Company NV, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about NewAmsterdam Pharma Company NV’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of NewAmsterdam Pharma Company NV.
How do we generate the risk management score of NewAmsterdam Pharma Company NV?
To assess the risk management score of NewAmsterdam Pharma Company NV, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of NewAmsterdam Pharma Company NV’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of NewAmsterdam Pharma Company NV.
